Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome

1 Jan 2021

Abstract excerpt

The NIH-funded Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer's Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD. These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Disease Management Strategies
Share to Down syndrome and intellectual disability research
Share to Frailty in Older Adults

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33336224
DOI: 10.14283/jpad.2020.35

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down SyndromePMID 33336224Read ↗

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodologySemantic proximity Read ↗

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudySemantic proximity Read ↗

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discoverySemantic proximity Read ↗

AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndromeSemantic proximity Read ↗

Alzheimer's disease in Down syndrome: An overlooked population for prevention trialsSemantic proximity Read ↗

Cognitive Changes associated with Alzheimer’s disease in Down syndromeSemantic proximity Read ↗

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.Semantic proximity Read ↗

From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approachSemantic proximity Read ↗

Aging in Down Syndrome and the Development of Alzheimer's Disease NeuropathologySemantic proximity Read ↗

Aging with Down Syndrome—Where Are We Now and Where Are We Going?Semantic proximity Read ↗

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.Semantic proximity Read ↗

Risk of Alzheimer's disease in Down syndrome: Insights gained by multi‐omicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.